Zacks Research Has Positive View of Alkermes FY2025 Earnings

Alkermes plc (NASDAQ:ALKS) – Analysts at Zacks Research lifted their FY2025 earnings per share estimates for Alkermes in a report released on Tuesday, July 1st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.55 for the year, up from their prior estimate of $1.54. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ FY2026 earnings at $1.98 EPS, Q1 2027 earnings at $0.32 EPS, Q2 2027 earnings at $0.48 EPS and FY2027 earnings at $1.68 EPS.

ALKS has been the topic of several other research reports. UBS Group upgraded shares of Alkermes from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $33.00 to $42.00 in a report on Tuesday, June 17th. Wall Street Zen downgraded shares of Alkermes from a “strong-buy” rating to a “buy” rating in a report on Monday, May 5th. Needham & Company LLC began coverage on shares of Alkermes in a report on Wednesday, May 28th. They set a “buy” rating and a $45.00 price objective on the stock. Robert W. Baird upped their price objective on shares of Alkermes from $38.00 to $41.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Finally, Royal Bank Of Canada upped their price objective on shares of Alkermes from $39.00 to $40.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Alkermes Stock Down 0.9%

Alkermes stock opened at $28.75 on Thursday. Alkermes has a 12-month low of $22.90 and a 12-month high of $36.45. The firm’s fifty day moving average is $30.12 and its 200 day moving average is $30.89. The company has a market capitalization of $4.74 billion, a PE ratio of 13.76, a PEG ratio of 1.79 and a beta of 0.44.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The firm had revenue of $306.51 million for the quarter, compared to the consensus estimate of $307.53 million. During the same quarter last year, the firm posted $0.43 earnings per share. The business’s revenue for the quarter was down 12.6% on a year-over-year basis.

Hedge Funds Weigh In On Alkermes

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Alkermes by 488.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company’s stock valued at $172,860,000 after purchasing an additional 4,345,523 shares during the period. Avoro Capital Advisors LLC bought a new stake in Alkermes in the 4th quarter worth $70,462,000. Nuveen LLC bought a new stake in Alkermes in the 1st quarter worth $66,689,000. Norges Bank bought a new stake in Alkermes in the 4th quarter worth $56,684,000. Finally, RTW Investments LP boosted its stake in shares of Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock valued at $217,363,000 after purchasing an additional 903,802 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Insiders Place Their Bets

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total transaction of $103,654.06. Following the completion of the transaction, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.40% of the stock is owned by corporate insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.